Nebentan

Nebentan Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 18916372613
Email: yanzihan@shyuanye.com
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774 400-920-5774
Email: sales@glpbio.cn
Company Name: ChemeGen(Shanghai) Biotechnology Co.,Ltd.  
Tel: 18818260767
Email: sales@chemegen.com
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com
Nebentan Basic information
Product Name:Nebentan
Synonyms:Nebentan;Nebentan free base;Ethenesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenyl-, (1E)-
CAS:403604-85-3
MF:C24H21N5O5S
MW:491.52
EINECS:
Product Categories:
Mol File:403604-85-3.mol
Nebentan Structure
Nebentan Chemical Properties
storage temp. Store at -20°C
solubility DMSO: 125 mg/mL (254.31 mM)
form Solid
color Light yellow to yellow
Safety Information
MSDS Information
Nebentan Usage And Synthesis
UsesNebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2].
in vivo

Nebentan (oral administration; 0.1-1 mg/kg; 4 weeks) significantly inhibits the progression of pulmonary hypertension and the development of right ventricular hypertrophy[2].Nebentan (oral administration; 1 mg/kg; 30 weeks) significantly ameliorates the poor survival rate of CHF rats, it markedly reduces the hypertrophy of both ventricles as well as pulmonary congestion[2].

IC 50ETA: 0.697 nM (Ki); ETB: 569 nM (Ki)
References[1] Hironori Yuyama, et al. Pharmacological Characterization of YM598, an Orally Active and Highly Potent Selective Endothelin ET(A) Receptor Antagonist. Eur J Pharmacol. 2003 Sep 30;478(1):61-71. DOI:10.1016/j.ejphar.2003.08.031
[2] Akira Fujimori, et al. YM598, an Orally Active ET(A) Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-Side Heart Failure in Rats With Cor Pulmonale and Myocardial Infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7. DOI:10.1097/01.fjc.0000166304.40937.0b
Nebentan Preparation Products And Raw materials
Tag:Nebentan(403604-85-3) Related Product Information
ET receptor antagonist 1 ET receptor antagonist 2 Nebentan potassium Nebentan Clazosentan EDNRA Protein-VLP, Human (HEK293)